A recent clinical trial published in Pharmacol Res has revealed that Lipoic Acid has the potential to reduce inflammation.

The study showed that the LA-induced effects were brought about by cAMP and protein kinase A (PKA) signaling. The researchers used a model of lipopolysaccharide (LPS) induced inflammation in mice to study the effects of Lipoic Acid. They found that pretreatment of the mice with LA reduced the production of inflammatory cytokines such as TNF-α, IL-1β and IL-6. Furthermore, they observed an increase in anti-inflammatory cytokines (IL-10 and TGF-β).

The results of the study suggest that LA may have anti-inflammatory properties and could be a potential therapeutic agent for the treatment of inflammatory conditions. The researchers concluded that further studies are needed to better understand the mechanism of action of LA and its potential therapeutic applications.

Overall, this study shows promise for the use of Lipoic Acid as an anti-inflammatory agent. Further research is needed to confirm these findings and to explore the potential therapeutic applications of LA.

Link to article:
https://pubmed.ncbi.nlm.nih.gov/35026405/